Gene Therapy Company Announces Positive Clinical Study Results From Lung Cancer Trials

Genprex, Inc., a clinical-stage gene therapy company, has recently announced significant updates from its ongoing Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials. These trials are focused on treating non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) respectively. The promising early results are seen as a potentially transformative development in the treatment of these challenging forms of lung cancer. $Genprex (GNPX.US)$